<DOC>
	<DOCNO>NCT00769067</DOCNO>
	<brief_summary>This study compare PF-00299804 give orally continuous schedule approve drug , erlotinib , patient whose non-small cell lung cancer progress chemotherapy ; patient randomize receive one drug , follow efficacy tolerance .</brief_summary>
	<brief_title>A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>advanced measurable NonSmall Cell Lung Cancer ( NSCLC ) ; progress 12 prior chemotherapy ; Eastern Cooperative Oncology Group ( ECOG ) 02 ; tissue available future KRAS/ EGFR test prior Epidermal Growth Factor Receptor ( EGFR ) target therapy ; active untreated Central Nervous System ( CNS ) metastases ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>second third line</keyword>
</DOC>